Clinical trials: Covid-19 Patients
Mild to Moderate COVID-19
A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of SNS812 in Participants with Mild to Moderate COVID-19
- Trial name
- NCT05941793
- Testing
- MBS-COV
- Where
- 5 sites in United States, Taiwan
- Volunteers
- 135 people
- Sponsor
- Oneness Biotech Co., Ltd.
Covid19
Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19)
Background - A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in December 2019 as the cause of a respiratory illness COVID-19 in Wuhan City, China.
- Trial name
- NCT04596839
- Testing
- Remdesivir, Standard of Care
- Where
- Bangladesh
- Volunteers
- 60 people
- Sponsor
- Dr. Md. Alimur Reza
COVID-19 Pneumonia
Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes
To evaluate the post-marketing immunogenicity, safety and antibody persistence of the third dose (booster) of Covid-19 vaccine in patients aged 60 years or older with hypertension and/or diabetes.
- Trial name
- NCT05104333
- Testing
- Covid-19 vaccine (0-1-4 schedule), Covid-19 vaccine (0-1-6 schedule)
- Where
- 5 sites in China
- Volunteers
- 1,440 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
COVID-19
The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19
The purpose of this clinical trial is to assess the safety and efficacy of Clevudine 120 mg versus placebo once daily administration with standard of care therapy for 14 days (maximum up to 21 days) in patients with moderate…
- Trial name
- NCT04347915
- Testing
- Clevudine
- Where
- South Korea
- Volunteers
- 64 people
- Sponsor
- Bukwang Pharmaceutical
Covid19
Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
The COMET-TAIL main study evaluated efficacy, safety, and tolerability of IM sotrovimab versus IV sotrovimab in high-risk patients for the treatment of mild/moderate COVID-19.
- Trial name
- NCT04913675
- Testing
- sotrovimab
- Where
- 50 sites in United States, France and 1 more
- Volunteers
- 1,065 people
- Sponsor
- Vir Biotechnology, Inc.
SARS-CoV-2 Infection
Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.
This is a randomized, double-blind, placebo-controlled study of RP7214 in patients with symptomatic mild SARS-CoV-2 infection, having at least one high-risk feature (e.g., age > 60 years, hypertension, diabetes mellitus, chronic…
- Trial name
- NCT05007236
- Testing
- RP7214 + Standard of care (SOC)
- Where
- 16 sites in India
- Volunteers
- 163 people
- Sponsor
- Rhizen Pharmaceuticals SA
Corona Virus Infection
Sarilumab COVID-19
Primary Objective: To evaluate the clinical efficacy of sarilumab relative to the control arm in adult participants hospitalized with severe or critical Coronavirus Disease 2019 (COVID-19).
- Trial name
- NCT04327388
- Testing
- Sarilumab SAR153191
- Where
- 47 sites in Argentina, Brazil and 9 more
- Volunteers
- 420 people
- Sponsor
- Sanofi
Covid19
Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients
This is a prospective, interventional, multi-centre, phase III, randomized, double blind, placebo-controlled, parallel design trial to evaluate the efficacy, safety and tolerability of favipiravir as adjunct ('add on') to…
- Trial name
- NCT04529499
- Testing
- AVIGAN
- Where
- 2 sites in Kuwait
- Volunteers
- 353 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Coronavirus Infection
Covid-19, Hospitalized, PatIents, Nasafytol
The objective of this study is to evaluate the effect and safety of NASAFYTOL® on COVID-19 positive hospitalized patients as a supportive supplementation to standard-of-care in improving clinical parameters safely during hospital…
- Trial name
- NCT04844658
- Testing
- NASAFYTOL®, FULTIUM® -D3 800, Strandard of care treatment
- Where
- Belgium
- Volunteers
- 51 people
- Sponsor
- Tilman S.A.
COVID 19 Disease
Tafenoquine in Patients With Mild to Moderate COVID-19
A clinical study to assess the efficacy and safety of oral tafenoquine compared to placebo in patients with mild to moderate COVID 19 disease.
- Trial name
- NCT04533347
- Testing
- Tafenoquine Oral Tablet
- Where
- 10 sites in United States
- Volunteers
- 86 people
- Sponsor
- 60 Degrees Pharmaceuticals LLC
COVID-19 Pneumonia, Impaired Respiratory Function
Study of Efficacy and Safety of MAS825 in Patients With COVID-19
This clinical study was designed to assess the efficacy and safety of MAS825 for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infected patients with coronavirus disease 2019 (COVID-19) pneumonia…
- Trial name
- MAS-COVID (NCT04382651)
- Testing
- MAS825, Standard of Care (SoC)
- Where
- 21 sites in United States
- Volunteers
- 140 people
- Sponsor
- Novartis Pharmaceuticals
COVID-19
The Efficacy and Safety of TADIOS as an Adjuvant Therapy in Patients Diagnosed With Mild to Moderate COVID-19
This study will assess the safety and efficacy and tolerability of TADIOS compared to placebo in patients with mild to moderate COVID-19.
- Trial name
- NCT05552625
- Testing
- TADIOS
- Where
- 6 sites in India
- Sponsor
- Helixmith Co., Ltd.
Acute Respiratory Distress Syndrome
Pilot Clinical Study of NOA-001 for ARDS (Acute Respiratory Distress Syndrome)
The primary object of this clinical study is to investigate the efficacy and the safety of NOA-001 in patients with ARDS (ARDS caused by Non-COVID-19 or COVID-19).
- Trial name
- NCT04804943
- Testing
- NOA-001
- Where
- Japan
- Volunteers
- 45 people
- Sponsor
- Toray Industries, Inc
Covid19
A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)
This is a Phase 2b multi-center, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of intravenous (IV) Allocetra-OTS 10x10^9 cells vs placebo (1:1) in adult hospitalized patients with severe or…
- Trial name
- NCT04922957
- Testing
- ALLOCETRA-OTS
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Enlivex Therapeutics Ltd.
COVID-19
A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19
This is a dose-finding, inferentially seamless Phase 1/2 study evaluating the safety, tolerability and efficacy of IBI314 in Ambulatory Patients with COVID-19.
- Trial name
- NCT05162365
- Testing
- IBI314
- Where
- 19 sites in United States
- Volunteers
- 248 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Covid19, Corona Virus Infection
Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19
Multi-center multinational-controlled study in Israel, Brazil, Spain, and South-Africa. 240 adult patients who suffer from moderate COVID-19 infection.
- Trial name
- CimetrA (NCT05037162)
- Testing
- Biochemistry blood test, Hematology blood test, D-Dimer test (coagulation)
- Where
- Israel
- Volunteers
- 240 people
- Sponsor
- MGC Pharmaceuticals d.o.o
Respiratory Disease, Asthma
Digital App for Telerehabilitation in Respiratory Diseases
The purpose of this study is to evaluate the feasibility and the mid-term effects of a pulmonary rehabilitation intervention, delivered by digital App, on quality of life of patients affected by respiratory diseases.
- Conditions
- Respiratory Disease, Asthma, Long COVID, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT05572346
- Testing
- Home-based telerehabilitation program delivered through digital devices
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- MedicAir Healthcare S.r.l.
ARDS Due to COVID-19
Surfactant-BL in Adult Acute Respiratory Distress Syndrome Due to COVID-19
The purpose of this study is to prove the efficacy and safety Surfactant-BL, administered by inhalation in adult hospitalized patients with ARDS due to COVID-19.
- Trial name
- NCT04568018
- Testing
- Surfactant
- Where
- Russia
- Volunteers
- 120 people
- Sponsor
- Biosurf LLC.
COVID-19 Infection
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19
This study is to explore the safety and efficacy of using UCMSC01 in patients with COVID-19 infection via IV stem cell administration.
- Trial name
- UMSC01 (NCT05501418)
- Testing
- Allogeneic umbilical cord mesenchymal stem cells, Controlled normal saline
- Where
- Taiwan
- Volunteers
- 75 people
- Sponsor
- Ever Supreme Bio Technology Co., Ltd.
Covid19
Bucillamine in Treatment of Patients With COVID-19
This is a Phase 3, multi-center, randomized, double blind, placebo controlled, clinical study of bucillamine (2 dosage levels) in patients with mild-moderate COVID-19.
- Trial name
- NCT04504734
- Testing
- Bucillamine
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 713 people
- Sponsor
- Revive Therapeutics, Ltd.